Results 201 to 210 of about 127,260 (361)

Evaluation of Diagnostic Accuracy of Directly Sampled Endometrial Cytology Using ThinPrep for Endometrial Malignancies: Comparison With Existing Endometrial Liquid‐Based Cytology

open access: yesCytopathology, EarlyView.
This study evaluated the diagnostic accuracy of directly sampled endometrial cytology using ThinPrep with a novel preparation method for detecting endometrial malignancies. The method yielded high‐quality cytology samples, and examiners with minimal experience demonstrated high diagnostic accuracy using the Yokohama System, supporting its global ...
Rie Ikemoto   +11 more
wiley   +1 more source

A comparison of proliferation markers and their prognostic value for women with endometrial carcinoma: Ki-67, proliferating cell nuclear antigen, and flow cytometric S-phase fraction [PDF]

open access: bronze, 1996
Britta Nordström   +4 more
openalex   +1 more source

GLP‐1 receptor agonists and the risk for cancer: A meta‐analysis of randomized controlled trials

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
Abstract Aims To assess if there is a difference in the oncogenic risk between GLP‐1 RA and comparators in randomized controlled trials. Materials and Methods A meta‐analysis of randomized controlled trials comparing GLP‐1RA to any comparators for diabetes and/or obesity, lasting at least 52 weeks.
Giovanni Antonio Silverii   +5 more
wiley   +1 more source

Y12C mutation disrupts IMPDH cytoophidia and alters cancer metabolism

open access: yesThe FEBS Journal, EarlyView.
IMPDH, the rate‐limiting enzyme for de novo GTP synthesis, can form polymers and cytoophidia to enhance activity by reducing GTP inhibition. In this study, a Y12C mutation in IMPDH2 was introduced via ABEmax base‐editing in human cancer cell lines to disrupt IMPDH polymerisation.
Chia‐Chun Chang   +7 more
wiley   +1 more source

A strong prognostic variable in endometrial carcinoma [PDF]

open access: bronze, 1997
Semih Kaleli   +7 more
openalex   +1 more source

The G protein‐coupled receptor GPR89A is a novel potential therapeutic target to overcome cisplatin resistance in NSCLC Calu1 cells

open access: yesThe FEBS Journal, EarlyView.
A genome‐wide CRISPR‐Cas9‐based genetic screen in cisplatin‐resistant NSCLC cells revealed 63 potential candidate genes for overcoming cisplatin resistance, including GPR89A. GPR89A, localised in the Golgi, modulates voltage‐gated anion channel activity and is involved in intracellular pH reduction.
Hale Guler Kara   +9 more
wiley   +1 more source

The role of routine pelvic lymph node sampling in patients with stage I endometrial carcinoma, second thoughts [PDF]

open access: bronze, 1998
Amiram Bar‐Am   +8 more
openalex   +1 more source

Correlating p53 immunostaining patterns with somatic TP53 mutation and functional properties of mutant p53 in triple‐negative breast cancer

open access: yesHistopathology, EarlyView.
This study introduces newly defined criteria for interpreting p53 IHC expression in triple‐negative breast cancer. These criteria could enable the prediction of TP53 mutation types and their functional implications, providing valuable insights for future clinical research and potentially improving stratification of treatment options for patients.
Meejeong Kim   +7 more
wiley   +1 more source

Home - About - Disclaimer - Privacy